title: Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.
abstract: The activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine against two virulent strains of the Mycobacterium avium complex isolated from patients with AIDS were evaluated in a model of intracellular infection and were compared with that of clarithromycin. Human monocyte-derived macrophages were infected with the M. avium complex at day 6 of culture. The intracellular CFU was counted 60 min after inoculation. The intracellular and supernatant CFU was counted on days 4 and 7 after inoculation. The concentrations used, which were equal to peak levels in serum, were 10 micrograms of rifapentine per ml (MICs for the two strains, 4 and 16 micrograms/ml), 4 micrograms of clarithromycin per ml (MICs, 8 and 4 micrograms/ml), 1 microgram of azithromycin per ml (MICs, 32 and 16 micrograms/ml), 4 micrograms of temafloxacin per ml (MICs, 2 and 16 micrograms/ml), and 1 microgram of sparfloxacin per ml (MICs, 0.5 and 2 micrograms/ml). Compared with controls on day 7 after inoculation, clarithromycin (P less than 0.001), sparfloxacin (P less than 0.001), and azithromycin (P less than 0.001 for the first strain, P less than 0.02 for the second) slowed intracellular replication. Rifapentine (P less than 0.001) and temafloxacin (P less than 0.001) slowed intracellular replication of the first strain but not of the second strain. Azithromycin plus sparfloxacin was as effective as sparfloxacin alone. In this macrophage model, sparfloxacin or clarithromycin (difference not significant) exhibited a better efficacy than rifapentine, azithromycin, or temafloxacin against intracellular M. avium complex infection.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale Unité 13, Hôpital Claude Bernard, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Perronne
authors.forename: A
authors.initials: A
authors.lastname: Gikas
authors.forename: C
authors.initials: C
authors.lastname: Truffot-Pernot
authors.forename: J
authors.initials: J
authors.lastname: Grosset
authors.forename: J L
authors.initials: JL
authors.lastname: Vilde
authors.forename: J J
authors.initials: JJ
authors.lastname: Pocidalo
mesh_terms: D042462:4-Quinolones; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin; D002455:Cell Division / Q000187:drug effects; D017291:Clarithromycin; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D066298:In Vitro Techniques; D007917:Leprostatic Agents / Q000494:pharmacology; D008264:Macrophages / Q000382:microbiology*; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D015363:Quinolones; D012293:Rifampin / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D007917:Leprostatic Agents; D015363:Quinolones; C054745:temafloxacin; D004917:Erythromycin; D017963:Azithromycin; D017291:Clarithromycin; D012293:Rifampin; C018421:rifapentine